METHODS FOR IMPROVING MUSCLE STRENGTH AND MOBILITY
Described are methods of improving muscle strength and mobility comprising administration of a fucosylated oligosaccharide.
1 . A method of improving muscle strength or mobility in a subject in need thereof comprising administering to said subject an effective amount of 2′-fucosyllactose (2′FL).
2 . The method of claim 1 , wherein the effective amount is an amount that increases the expression of CEBPB.
3 . The method of claim 1 , wherein the subject is a human subject.
4 . The method of claim 3 , wherein the subject is suffering from low muscle mass or impaired physical mobility.
5 . The method of claim 1 , wherein the subject is suffering from and/or diagnosed with a condition selected from the group consisting of frailty or frailty syndrome, pre-frailty, sarcopenia, age-related muscle loss, metabolic syndrome, and a condition resulting in muscle atrophy and/or fatigue.
6 . The method of claim 1 , wherein the subject is suffering from and/or diagnosed with drug-induced muscle weakness or myopathy.
7 . (canceled)
8 . The method of claim 1 , wherein the subject is suffering from muscle weakness associated with infection.
9 . (canceled)
10 . The method of claim 1 , wherein the subject is suffering from muscle weakness associated with an endocrine condition, an inflammatory condition, a rheumatologic condition, an electrolyte syndrome, a neuromuscular condition, a neurological condition, or a genetic condition.
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . The method of claim 4 , wherein the impaired physical mobility is due to stroke, rheumatoid arthritis, osteoarthritis, osteoporosis, osteopenia, limb fracture, multiple sclerosis, trauma, sepsis, or obesity.
19 . The method of claim 4 , wherein the impaired mobility is due to aging.
20 . The method of and claim 2 , wherein the subject has reduced CEBPB expression level prior to the initiation of the treatment, wherein the reduced CEBPB expression level is reduced as compared to a control expression level.
21 . The method of claim 20 , wherein the expression level is detected by measuring RNA.
22 . The method of claim 20 , the method further comprising obtaining a biological sample from the subject prior to the initiation of the treatment, detecting the expression level of CEBPB in the biological sample, and determining that the expression level of CEBPB is lower than that of the control expression level.
23 . The method of claim 1 , wherein the expression level of CEBPB increases after the initiation of the therapy.
24 . The method of claim 1 , wherein the subject is an adult.
25 . (canceled)
26 . (canceled)
27 . The method of claim 1 , wherein the treatment improves the subject's muscle strength or mobility as measured by lower handgrip muscle strength, short physical performance battery (SPPB) score, Timed Up and Go test (TUGT), walking speed (WS), and/or grip strength (GS).
28 . The method of claim 1 , wherein the 2′FL is administered orally.
29 . The method of claim 1 , wherein the amount of 2′FL is from 1 g to about 20 g per day.
30 . The method of claim 1 , wherein the 2′FL is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipients, wherein the pharmaceutical composition is not mammalian milk.
31 . A method of increasing CEPBP expression in a subject in need thereof comprising administering to said subject an effective amount of 2′-fucosyllactose (2′FL).
32 . The method of claim 31 , wherein the effective amount is an amount that increases the expression of CEBPB.
33 . The method of claim 31 , wherein the subject is a human subject.
34 . The method of claim 31 , wherein the subject is suffering from low muscle mass or impaired physical mobility.
35 . The method of claim 31 , wherein the subject is suffering from and/or diagnosed with a condition selected from the group consisting of frailty or frailty syndrome, pre-frailty, sarcopenia, age-related muscle loss, metabolic syndrome, and a condition resulting in muscle atrophy and/or fatigue.
36 . The method of claim 31 , wherein the subject is suffering from and/or diagnosed with drug-induced muscle weakness or myopathy.
37 . (canceled)
38 . The method of claim 31 , wherein the subject is suffering from and/or diagnosed with muscle weakness associated with infection.
39 . (canceled)
40 . The method of claim 31 , wherein the subject is suffering from muscle weakness associated with an endocrine condition, an inflammatory condition, a rheumatologic conditions, an electrolyte syndrome, a neuromuscular condition, a neurological condition, or a genetic condition.
41 . (canceled)
42 . (canceled)
43 . (canceled)
44 . (canceled)
45 . (canceled)
46 . The method of claim 35 , wherein the age-related muscle loss is at least partially due to diabetes or obesity.
47 . (canceled)
48 . (canceled)
49 . (canceled)
50 . The method of claim 31 , wherein the subject is at risk of impaired physical mobility, muscle loss, or muscle weakness.
51 . (canceled)
52 . (canceled)
53 . (canceled)
54 . (canceled)
55 . The method of and claim 31 , wherein the subject has reduced CEBPB expression as compared to a control expression level prior to the initiation of the treatment.
56 . The method of claim 55 , wherein the expression level is detected by measuring RNA.
57 . The method of claim 55 , comprising obtaining a biological sample from the subject prior to the initiation of the therapy, detecting the expression level of CEBPB in the biological sample, and determining that the expression level of CEBPB is lower than that of the control express level prior to the initiation of the treatment.
58 . The method of claim 31 , wherein the expression level of CEBPB increases after the initiation of the therapy.
59 . The method of claim 1 , wherein the subject is an adult.
60 . (canceled)
61 . The method of claim 31 , wherein the treatment improves the subject's muscle strength or mobility as measured by lower handgrip muscle strength, short physical performance battery (SPPB) score, Timed Up and Go test (TUGT), walking speed (WS), and/or grip strength (GS).
62 . The method of claim 31 , wherein the 2′FL is administered orally.
63 . The method of claim 31 , wherein the amount of 2′FL is from 1 g to about 20 g per day.
64 . The method of claim 31 , wherein the 2′FL is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipients, wherein the pharmaceutical composition is not mammalian milk.